Data from Phase 1b dose escalation and expansion trial (n=69) shows a favorable safety profile, with manageable adverse events consistent with ...
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts ...
Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating AVZO-023 (CDK4i) with AVZO-021 (CDK2i) In Phase 1/2 ORION-1 Study ...
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse eventsActivity of the combined regimen ...
SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company developing rationally designed molecular glue ...
London: Doctors on Saturday praised "unprecedentedly strong responses" to an injection that eradicated entire tumours in ...
A targeted cancer treatment given via a simple injection under the skin shrank tumours in more than one third of patients with recurrent and/or metastatic head and neck cancer whose disease has ...
An oral medication already approved for thrombocytopenia in patients with liver disease significantly improved platelet ...
Doctors explain the most common causes of hair loss, from stress and thyroid issues to medications, menopause, and nutrient ...
Doctors have praised “unprecedentedly strong responses” to an injection that eradicated entire tumours in otherwise treatment- resistant cancer cases during a trial.It shrank the tumours for 42% of ...
Researchers have tested a gene-edited stem cell transplant designed to shield healthy blood-forming cells from powerful ...
An oral medication already approved for thrombocytopenia in patients with liver disease significantly improved platelet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results